Why the study?
Although mitochondrial fatty acid β-oxidation deficits are thought to induce mitochondrial stress and activate mitophagy, the mechanistic link in the heart remains unclear.
Does deletion of USP30 improve cardiac function and survival in a mouse model of fatty acid oxidation-deficient cardiomyopathy?
Does deletion of USP30 improve cardiac function and survival in a mouse model of fatty acid oxidation-deficient cardiomyopathy?
Inhibition of USP30 restores mitophagy and improves cardiac function and survival in a preclinical model of fatty acid oxidation-deficient cardiomyopathy, highlighting a potential therapeutic target.
Questions mitophagy activation in FAO-deficient cardiomyopathy; leaves open mechanistic validation before therapeutic targeting.
The healthy heart relies on mitochondrial fatty acid β-oxidation (FAO) to sustain its high energy demands. FAO deficiencies can cause muscle weakness, cardiomyopathy, and, in severe cases, neonatal/infantile mortality. Although FAO deficits are thought to induce mitochondrial stress and activate mitophagy, a quality control mechanism that eliminates damaged mitochondria, the mechanistic link in the heart remains unclear. Here we show that mitophagy is unexpectedly suppressed in FAO-deficient hearts despite pronounced mitochondrial stress, using a cardiomyocyte-specific carnitine palmitoyltransferase 2 (CPT2) knockout model. Multi-omics profiling reveals impaired PINK1/Parkin signaling and dysregulation of PARL, a mitochondrial protease essential for PINK1 processing. Strikingly, deletion of USP30, a mitochondrial deubiquitinase that antagonizes PINK1/Parkin function, restores mitophagy, improves cardiac function, and significantly extends survival in FAO-deficient animals. These findings redefine the mitophagy response in FAO-deficient hearts and establish USP30 as a promising therapeutic target for metabolic cardiomyopathies and broader heart failure characterized by impaired FAO. The heart relies on fatty acid oxidation as its main energy source. Here they show that impaired fatty acid metabolism disrupts mitophagy in the heart and that enhancing mitophagy via USP30 inhibition can restore heart function in models of fatty acid oxidation deficiency.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2025) studied FAO-deficient cardiomyopathy. USP30 deletion vs. CPT2H-KO mice (FAO-deficient without USP30 deletion) was evaluated on Survival and cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: